“Meropenem/amikacin combination therapy vs monotherapies: A metabolomic analysis of effects on multidrug-resistant P. aeruginosa”

https://pubmed.ncbi.nlm.nih.gov/38116135

Metabolomic analysis shows that meropenem/amikacin combination therapy against multidrug-resistant P. aeruginosa strains harboring OXA-50 and PAO genes significantly alters metabolic pathways essential for bacterial survival, more so than monotherapies.